Trial Profile
A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2019 Planned number of patients changed from 45 to 26.